Table 1 Response rates and MRD-negativity rates in the ITT population.

From: Daratumumab/lenalidomide/dexamethasone in transplant-ineligible newly diagnosed myeloma: MAIA long-term outcomes

 

D-Rd (n = 368)

Rd (n = 369)

P value

Response, n (%)

 ORR

342 (92.9)

301 (81.6)

< 0.0001a

  ≥CR

188 (51.1)

111 (30.1)

< 0.0001a

   sCR

131 (35.6)

58 (15.7)

< 0.0001a

   CR

57 (15.5)

53 (14.4)

 

  ≥VGPR

300 (81.5)

210 (56.9)

< 0.0001a

   VGPR

112 (30.4)

99 (26.8)

 

  PR

42 (11.4)

91 (24.7)

 

 SD

11 (3.0)

55 (14.9)

 

 PD

1 (0.3)

0

 

 NE

14 (3.8)

13 (3.5)

 

MRD negative (10–5), n (%)

118 (32.1)

41 (11.1)

< 0.0001b

Sustained MRD negative (10–5), n (%)

 Lasting ≥12 months

69 (18.8)

15 (4.1)

< 0.0001b

 Lasting ≥18 months

62 (16.8)

12 (3.3)

< 0.0001b

  1. MRD minimal residual disease, ITT intent-to-treat, D-Rd daratumumab plus lenalidomide/dexamethasone, Rd lenalidomide/dexamethasone, ORR overall response rate, CR complete response, sCR stringent complete response, VGPR very good partial response, PR partial response, SD stable disease, PD progressive disease, NE not evaluable.
  2. aP value was calculated using the Cochran–Mantel–Haenszel chi-square test.
  3. bP value was calculated using the Fisher’s exact test.
Back to article page